CoChat
Sign Up
Cited by 57

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Novel Apo E-Derived ABCA1 Agonist Peptide (CS-6253) Promotes Reverse Cholesterol Transport and Induces Formation of preβ-1 HDL In Vitro

Hafiane, Anouar, Bielicki, John K., Johansson, Jan O., Genest, Jacques·2015·PLOS ONE
DOI 10.1371/journal.pone.0131997PMC PMC4514675
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0131997

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 1 references

Research works printed but not linked: 83

  1. DJ Rader, 2009, The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis, J Lipid Res, 50, S189, 10.1194/jlr.R800088-JLR200 · DOI
  2. LJ Leman, 2014, Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis, J Med Chem, 57, 2169, 10.1021/jm4005847 · DOI
  3. GS Getz, 2010, Biological properties of apolipoprotein a-I mimetic peptides, Curr Atheroscler Rep, 12, 96, 10.1007/s11883-010-0097-4 · DOI
  4. A Hafiane, 2014, Treatment options for low high-density lipoproteins, Current opinion in endocrinology, diabetes, and obesity, 21, 134, 10.1097/MED.0000000000000049 · DOI
  5. GS Getz, 2009, Apoprotein A-I mimetic peptides and their potential anti-atherogenic mechanisms of action, Curr Opin Lipidol, 20, 171, 10.1097/MOL.0b013e32832ac051 · DOI
  6. AT Remaley, 2008, HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications, Expert Rev Cardiovasc Ther, 6, 1203, 10.1586/14779072.6.9.1203 · DOI
  7. JK Bielicki, 2010, A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice, J Lipid Res, 51, 1496, 10.1194/jlr.M003665 · DOI
  8. AT Remaley, 2003, Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway, J Lipid Res, 44, 828, 10.1194/jlr.M200475-JLR200 · DOI
  9. MJ Amar, 2010, 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice, J Pharmacol Exp Ther, 334, 634, 10.1124/jpet.110.167890 · DOI
  10. Y Zheng, 2011, HDL mimetic peptide ATI-5261 forms an oligomeric assembly in solution that dissociates to monomers upon dilution, Biochemistry, 50, 4068, 10.1021/bi2002955 · DOI
  11. A Hafiane, 2014, Apolipoprotein E derived HDL mimetic peptide ATI-5261 promotes nascent HDL formation and reverse cholesterol transport in vitro, Biochim Biophys Acta, 1842, 1498, 10.1016/j.bbalip.2014.07.018 · DOI
  12. JF Oram, 2001, ATP-binding cassette transporter A1 mediates cellular secretion of alpha-tocopherol, J Biol Chem, 276, 39898, 10.1074/jbc.M106984200 · DOI
  13. AM Vaughan, 2006, ABCA1 and ABCG1 or ABCG4 act sequentially to remove cellular cholesterol and generate cholesterol-rich HDL, J Lipid Res, 47, 2433, 10.1194/jlr.M600218-JLR200 · DOI
  14. L Kritharides, 1998, Cholesterol metabolism and efflux in human THP-1 macrophages, Arterioscler Thromb Vasc Biol, 18, 1589, 10.1161/01.ATV.18.10.1589 · DOI
  15. M Denis, 2004, Characterization of oligomeric human ATP binding cassette transporter A1. Potential implications for determining the structure of nascent high density lipoprotein particles, J Biol Chem, 279, 41529, 10.1074/jbc.M406881200 · DOI
  16. L Krimbou, 2004, Molecular interactions between apoE and ABCA1: impact on apoE lipidation, J Lipid Res, 45, 839, 10.1194/jlr.M300418-JLR200 · DOI · Paper page
  17. OH Lowry, 1951, Protein measurement with the Folin phenol reagent, J Biol Chem, 193, 265, 10.1016/S0021-9258(19)52451-6 · DOI
  18. A Hafiane, 2014, High-density lipoprotein mediated cellular cholesterol efflux in acute coronary syndromes, Am J Cardiol, 113, 249, 10.1016/j.amjcard.2013.09.006 · DOI
  19. RJ Doonan, 2014, Cholesterol efflux capacity, carotid atherosclerosis, and cerebrovascular symptomatology, Arterioscler Thromb Vasc Biol, 34, 921, 10.1161/ATVBAHA.113.302590 · DOI
  20. D Bailey, 2010, Analysis of lipid transfer activity between model nascent HDL particles and plasma lipoproteins: implications for current concepts of nascent HDL maturation and genesis, J Lipid Res, 51, 785, 10.1194/jlr.M001875 · DOI
  21. HH Hassan, 2008, Quantitative analysis of ABCA1-dependent compartmentalization and trafficking of apolipoprotein A-I: implications for determining cellular kinetics of nascent high density lipoprotein biogenesis, J Biol Chem, 283, 11164, 10.1074/jbc.M707720200 · DOI
  22. FT Hatch, 1968, Practical methods for plasma lipoprotein analysis, Adv Lipid Res, 6, 1
  23. L Krimbou, 1997, Characterization of human plasma apolipoprotein E-containing lipoproteins in the high density lipoprotein size range: focus on pre-beta1-LpE, pre-beta2-LpE, and alpha-LpE, J Lipid Res, 38, 35, 10.1016/S0022-2275(20)37273-4 · DOI · Paper page
  24. M Denis, 2004, Molecular and cellular physiology of apolipoprotein A-I lipidation by the ATP-binding cassette transporter A1 (ABCA1), J Biol Chem, 279, 7384, 10.1074/jbc.M306963200 · DOI
  25. F Zimetti, 2006, Measurement of cholesterol bidirectional flux between cells and lipoproteins, J Lipid Res, 47, 605, 10.1194/jlr.M500466-JLR200 · DOI
  26. A Hafiane, 2014, Apolipoprotein E derived HDL mimetic peptide ATI-5261 promotes nascent HDL formation and reverse cholesterol transport in vitro, Biochim Biophys Acta
  27. BK Nordskog, 1999, Sterol synthesis is up-regulated in cholesterol-loaded pigeon macrophages during induction of cholesterol efflux, J Lipid Res, 40, 1806, 10.1016/S0022-2275(20)34897-5 · DOI
  28. ET Alexander, 2011, Influence of apolipoprotein A-I domain structure on macrophage reverse cholesterol transport in mice, Arterioscler Thromb Vasc Biol, 31, 320, 10.1161/ATVBAHA.110.216226 · DOI
  29. PG Yancey, 2000, High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI, J Biol Chem, 275, 36596, 10.1074/jbc.M006924200 · DOI
  30. TJ Nieland, 2002, Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI, Proc Natl Acad Sci U S A, 99, 15422, 10.1073/pnas.222421399 · DOI
  31. AA Sethi, 2008, Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides, J Biol Chem, 283, 32273, 10.1074/jbc.M804461200 · DOI
  32. A Hafiane, 2013, HDL, Atherosclerosis, and Emerging Therapies, Cholesterol, 2013, 891403, 10.1155/2013/891403 · DOI
  33. JD Smith, 2010, Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis, Curr Opin Investig Drugs, 11, 989
  34. I Iatan, 2011, Membrane microdomains modulate oligomeric ABCA1 function: impact on apoAI-mediated lipid removal and phosphatidylcholine biosynthesis, J Lipid Res, 52, 2043, 10.1194/jlr.M016196 · DOI
  35. L Krimbou, 2005, Biogenesis and speciation of nascent apoA-I-containing particles in various cell lines, J Lipid Res, 46, 1668, 10.1194/jlr.M500038-JLR200 · DOI
  36. HH Hassan, 2006, Cellular cholesterol homeostasis in vascular endothelial cells, Can J Cardiol, 22, 35B, 10.1016/S0828-282X(06)70985-0 · DOI
  37. R Liu, 2007, Macrophage phospholipid transfer protein deficiency and ApoE secretion: impact on mouse plasma cholesterol levels and atherosclerosis, Arterioscler Thromb Vasc Biol, 27, 190, 10.1161/01.ATV.0000249721.96666.e5 · DOI
  38. Y Liu, 2012, Regulation of ABCA1 functions by signaling pathways, Biochim Biophys Acta, 1821, 522, 10.1016/j.bbalip.2011.08.015 · DOI
  39. S Diditchenko, 2013, Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux, Arterioscler Thromb Vasc Biol, 33, 2202, 10.1161/ATVBAHA.113.301981 · DOI
  40. C Tardy, 2014, CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice, Atherosclerosis, 232, 110, 10.1016/j.atherosclerosis.2013.10.018 · DOI
  41. MP Adorni, 2007, The roles of different pathways in the release of cholesterol from macrophages, J Lipid Res, 48, 2453, 10.1194/jlr.M700274-JLR200 · DOI
  42. C Vedhachalam, 2007, The C-terminal lipid-binding domain of apolipoprotein E is a highly efficient mediator of ABCA1-dependent cholesterol efflux that promotes the assembly of high-density lipoproteins, Biochemistry, 46, 2583, 10.1021/bi602407r · DOI
  43. T Mazzone, 1996, Apolipoprotein E secretion by macrophages: its potential physiological functions, Curr Opin Lipidol, 7, 303, 10.1097/00041433-199610000-00008 · DOI
  44. S Nandi, 2009, ABCA1-mediated cholesterol efflux generates microparticles in addition to HDL through processes governed by membrane rigidity, J Lipid Res, 50, 456, 10.1194/jlr.M800345-JLR200 · DOI
  45. GD Wool, 2008, Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties, J Lipid Res, 49, 1268, 10.1194/jlr.M700552-JLR200 · DOI
  46. DO Sviridov, 2013, Hydrophobic amino acids in the hinge region of the 5A apolipoprotein mimetic peptide are essential for promoting cholesterol efflux by the ABCA1 transporter, J Pharmacol Exp Ther, 344, 50, 10.1124/jpet.112.198143 · DOI
  47. GS Getz, 2014, The structure/function of apoprotein A-I mimetic peptides: an update, Curr Opin Endocrinol Diabetes Obes, 21, 129, 10.1097/MED.0000000000000045 · DOI
  48. PG Yancey, 1995, Efflux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class A amphipathic peptides, Biochemistry, 34, 7955, 10.1021/bi00024a021 · DOI
  49. AR Tall, 2002, Regulation and mechanisms of macrophage cholesterol efflux, J Clin Invest, 110, 899, 10.1172/JCI0216391 · DOI
  50. JF Oram, 1996, Apolipoprotein-mediated removal of cellular cholesterol and phospholipids, J Lipid Res, 37, 2473, 10.1016/S0022-2275(20)37453-8 · DOI
  51. XH Liu, 2010, Contribution of D4-F to ABCA1 expression and cholesterol efflux in THP-1 macrophage-derived foam cells, J Cardiovasc Pharmacol, 56, 309, 10.1097/FJC.0b013e3181edaf69 · DOI
  52. AJ Lusis, 2000, Atherosclerosis, Nature, 407, 233, 10.1038/35025203 · DOI
  53. H Tavori, 2015, Macrophage apoAI protects against dyslipidemia-induced dermatitis and atherosclerosis without affecting HDL, J Lipid Res
  54. CK Tang, 2004, Effect of apolipoprotein A-I on ATP binding cassette transporter A1 degradation and cholesterol efflux in THP-1 macrophage-derived foam cells, Acta Biochim Biophys Sin (Shanghai), 36, 218, 10.1093/abbs/36.3.218 · DOI
  55. KO Nagata, 2013, ABCA1 dimer-monomer interconversion during HDL generation revealed by single-molecule imaging, Proc Natl Acad Sci U S A, 110, 5034, 10.1073/pnas.1220703110 · DOI
  56. D Trompier, 2006, Transition from dimers to higher oligomeric forms occurs during the ATPase cycle of the ABCA1 transporter, J Biol Chem, 281, 20283, 10.1074/jbc.M601072200 · DOI
  57. MG Sorci-Thomas, 2012, High density lipoprotein biogenesis, cholesterol efflux, and immune cell function, Arterioscler Thromb Vasc Biol, 32, 2561, 10.1161/ATVBAHA.112.300135 · DOI
  58. AT Remaley, 2001, Apolipoprotein specificity for lipid efflux by the human ABCAI transporter, Biochem Biophys Res Commun, 280, 818, 10.1006/bbrc.2000.4219 · DOI
  59. R Arakawa, 2004, Phosphorylation and stabilization of ATP binding cassette transporter A1 by synthetic amphiphilic helical peptides, J Biol Chem, 279, 6217, 10.1074/jbc.C300553200 · DOI
  60. MC Phillips, 2013, New insights into the determination of HDL structure by apolipoproteins: Thematic review series: high density lipoprotein structure, function, and metabolism, J Lipid Res, 54, 2034, 10.1194/jlr.R034025 · DOI
  61. C Vedhachalam, 2007, Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles, J Biol Chem, 282, 25123, 10.1074/jbc.M704590200 · DOI
  62. CR White, 2012, Regulation of pattern recognition receptors by the apolipoprotein A-I mimetic peptide 4F, Arteriosclerosis, thrombosis, and vascular biology, 32, 2631, 10.1161/ATVBAHA.112.300167 · DOI
  63. LE Smythies, 2010, Apolipoprotein A-I mimetic 4F alters the function of human monocyte-derived macrophages, Am J Physiol Cell Physiol, 298, C1538, 10.1152/ajpcell.00467.2009 · DOI
  64. MG Sorci-Thomas, 2012, Nascent high density lipoproteins formed by ABCA1 resemble lipid rafts and are structurally organized by three apoA-I monomers, J Lipid Res, 53, 1890, 10.1194/jlr.M026674 · DOI
  65. S Lund-Katz, 2013, Mechanisms responsible for the compositional heterogeneity of nascent high density lipoprotein, J Biol Chem, 288, 23150, 10.1074/jbc.M113.495523 · DOI
  66. C Cavelier, 2006, Lipid efflux by the ATP-binding cassette transporters ABCA1 and ABCG1, Biochim Biophys Acta, 1761, 655, 10.1016/j.bbalip.2006.04.012 · DOI
  67. M de la Llera-Moya, 2010, The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages, Arterioscler Thromb Vasc Biol, 30, 796, 10.1161/ATVBAHA.109.199158 · DOI
  68. O Miyazaki, 2014, Evidence for the presence of lipid-free monomolecular apolipoprotein A-1 in plasma, J Lipid Res, 55, 214, 10.1194/jlr.M041038 · DOI
  69. E Favari, 2009, Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1, Biochemistry, 48, 11067, 10.1021/bi901564g · DOI · Paper page
  70. L Calabresi, 2010, Lecithin:cholesterol acyltransferase, high-density lipoproteins, and atheroprotection in humans, Trends Cardiovasc Med, 20, 50, 10.1016/j.tcm.2010.03.007 · DOI · Paper page
  71. AD Dergunov, 2013, Sequence-specific apolipoprotein A-I effects on lecithin:cholesterol acyltransferase activity, Mol Cell Biochem, 378, 283, 10.1007/s11010-013-1619-5 · DOI
  72. GM Anantharamaiah, 1985, Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine, J Biol Chem, 260, 10248, 10.1016/S0021-9258(17)39238-4 · DOI
  73. DW Garber, 1992, Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats. Correlation with physical properties, Arterioscler Thromb, 12, 886, 10.1161/01.ATV.12.8.886 · DOI
  74. X Chen, 2009, An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration, International journal of biological sciences, 5, 489, 10.7150/ijbs.5.489 · DOI
  75. DJ Bolin, 1996, Sphingomyelin inhibits the lecithin-cholesterol acyltransferase reaction with reconstituted high density lipoproteins by decreasing enzyme binding, J Biol Chem, 271, 19152, 10.1074/jbc.271.32.19152 · DOI
  76. JA de Souza, 2008, Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity, Atherosclerosis, 197, 84, 10.1016/j.atherosclerosis.2007.08.009 · DOI
  77. JS Troutt, 2008, An apolipoprotein A-I mimetic dose-dependently increases the formation of prebeta1 HDL in human plasma, J Lipid Res, 49, 581, 10.1194/jlr.M700385-JLR200 · DOI
  78. M Kawano, 1993, Quantitation of pre beta-HDL-dependent and nonspecific components of the total efflux of cellular cholesterol and phospholipid, Biochemistry, 32, 5025, 10.1021/bi00070a008 · DOI
  79. R Waksman, 2010, A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome, J Am Coll Cardiol, 55, 2727, 10.1016/j.jacc.2009.12.067 · DOI
  80. P Kee, 2002, Metabolism of apoA-I as lipid-free protein or as component of discoidal and spherical reconstituted HDLs: studies in wild-type and hepatic lipase transgenic rabbits, Arterioscler Thromb Vasc Biol, 22, 1912, 10.1161/01.ATV.0000038485.94020.7F · DOI
  81. M Wroblewska, 2011, The origin and metabolism of a nascent pre-beta high density lipoprotein involved in cellular cholesterol efflux, Acta Biochim Pol, 58, 275, 10.18388/abp.2011_2237 · DOI
  82. X Song, 2009, An apoA-I mimetic peptide facilitates off-loading cholesterol from HDL to liver cells through scavenger receptor BI, Int J Biol Sci, 5, 637, 10.7150/ijbs.5.637 · DOI
  83. SW Law, 1983, cDNA cloning of human apoA-I: amino acid sequence of preproapoA-I, Biochem Biophys Res Commun, 112, 257, 10.1016/0006-291X(83)91824-7 · DOI

Cited by

Sorted by citations

See all 57

Metadata

Authors
Hafiane, A., Bielicki, J. K., Johansson, J. O., & Genest, J.
Venue
PLOS ONE
Publisher
Public Library of Science (PLoS)
Published
2015-07-24
Volume
10
Issue
7
Pages
e0131997
ISSN
1932-6203
DOI
10.1371/journal.pone.0131997
PMC
PMC4514675
Cited by
57
References
1
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review